Shuttle Pharmaceuticals faces Nasdaq noncompliance under Listing Rule 5250(c)(1) after delaying its Form 10-Q for the period ended June 30, 2026. The common stock remains listed and tradable for now, but failure to regain compliance could lead to delisting, while the company must submit a corrective plan by October 27, 2026.
Key Highlights
- Shuttle Pharmaceuticals must provide Nasdaq with a plan to regain compliance by October 27, 2026.
- The common stock remains listed and tradable, although a noncompliance indicator will be distributed through Nasdaq market data channels.
- Nasdaq may allow compliance to continue through February 22, 2027, if it accepts the company’s plan.
Nasdaq Compliance Issue
Shuttle Pharmaceuticals is facing an issue under Nasdaq Listing Rule 5250(c)(1), creating a compliance matter for the company while its common stock remains listed and tradable for now. The situation does not currently remove the stock from trading, but it places the company under a Nasdaq process focused on restoring compliance.
The company’s continued listing status is therefore separate from the unresolved compliance requirement. Investors can still see the common stock listed and traded for now, while Nasdaq evaluates the company’s response and any steps it may take under the applicable rule.
Plan Deadline Set for October 27
Nasdaq gave Shuttle Pharmaceuticals until October 27, 2026, to present a plan describing how it expects to restore compliance. The plan is intended to explain the company’s expected approach rather than represent a completed return to compliance.
That deadline is the next stated milestone in the process. Shuttle Pharmaceuticals will need to provide Nasdaq with its proposed path by that date, while the available information does not establish whether Nasdaq will accept the plan or whether the company will ultimately satisfy the requirement.
Possible Extension Through February 22
Nasdaq may approve an exception that would extend the compliance period through February 22, 2027. The potential extension gives the company another stated period in which compliance could be pursued, but it is not an automatic outcome.
Acceptance of the exception is not assured. Even if Nasdaq approves the additional period, the company’s ability to meet the requirement within that extension is also uncertain, leaving the compliance issue unresolved until Nasdaq’s process produces a further result.
Trading Continues for Now
Shuttle Pharmaceuticals’ common stock remains listed and tradable for now, even though delisting risk remains. This means the current trading status has not ended, but it should not be read as confirmation that the company has restored compliance with Nasdaq’s requirement.
The article identifies the situation as an ongoing listing matter rather than an immediate change to the stock’s trading status. Investors therefore have a continuing distinction to track between the stock’s present availability for trading and the unresolved risk connected with Nasdaq compliance.
Noncompliance Market Indicator
Nasdaq will identify Shuttle Pharmaceuticals as noncompliant through its market data dissemination network. The indicator will also be available to third-party market data providers, allowing the noncompliance status to be reflected through those market data channels.
This identification is a disclosure of the company’s Nasdaq status and does not itself state that trading has already stopped. The company remains listed and tradable for now, while the market data indicator communicates that the compliance issue is still outstanding.
Expected Listing on Nasdaq’s Noncompliant Companies List
Shuttle Pharmaceuticals is expected to appear on Nasdaq’s list of noncompliant companies beginning around September 4, 2026. That expected listing follows Nasdaq’s decision to identify the company as noncompliant through its market data dissemination network.
The expected appearance on the list does not remove the October 27 plan deadline or change the possibility of an exception through February 22, 2027. It instead marks another visible point in the compliance process, with delisting risk remaining while the company works to address the requirement.
Peers Moving on This News
- Onconetix, Inc. (NASDAQ: ONCO) up 0.5%
- Oragenics Inc. (AMEX: OGEN) down 0.7%
- Vitaspring Biomedical Co. Ltd (OTC: VSBC) little changed




Please wait processing your request...